Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Risperidone
Drug ID BADD_D01951
Description Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder.[L12885] It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[L1212,L1213] Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.[L1213,A1115] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors,[L1212,L1213,A1115] and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.[L12885]
Indications and Usage Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885] Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906] Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]
Marketing Status approved; investigational
ATC Code N05AX08
DrugBank ID DB00734
KEGG ID D00426
MeSH ID D018967
PubChem ID 5073
TTD Drug ID D01AZG
NDC Product Code 12578-303; 57451-1185; 64567-0003; 65757-728; 65862-365; 12496-0090; 13668-035; 13668-039; 50458-306; 50458-325; 51759-410; 55700-897; 59746-050; 65841-670; 68071-2706; 68084-277; 69238-2108; 70518-1613; 70518-2969; 70518-3741; 71610-045; 71610-246; 0615-8197; 0615-8265; 0904-6360; 63552-180; 42291-913; 49884-315; 51759-850; 55154-4161; 59746-010; 63304-950; 63629-2283; 68084-271; 68382-154; 69238-2113; 70518-1151; 55111-869; 65267-895; 65757-727; 27241-004; 27241-005; 27241-006; 42291-908; 50458-335; 50458-355; 51759-305; 51759-520; 58118-0077; 59746-040; 63629-2284; 65841-642; 65841-668; 0054-0063; 68084-270; 70518-0364; 70518-3087; 70518-3760; 55154-3361; 55154-5899; 63187-264; 63187-642; 63304-643; 65862-167; 68084-273; 71335-0130; 0615-8196; 0904-6358; 71161-131; 27241-003; 49884-403; 50458-302; 50458-308; 51759-960; 63187-439; 68382-155; 70518-1502; 71205-520; 71335-0626; 0904-6361; 65757-725; 13668-037; 27808-002; 43063-908; 43547-344; 49884-311; 49884-401; 54838-563; 59746-030; 63304-951; 65841-641; 65841-667; 68084-272; 70518-1574; 70518-1771; 71610-259; 0615-8198; 72526-102; 72526-104; 63415-0037; 63552-179; 64220-119; 64552-4011; 42291-911; 43547-343; 49884-402; 50458-300; 50458-315; 50458-395; 51759-630; 53002-1596; 65841-640; 65841-666; 68084-274; 68382-114; 68382-115; 70518-1575; 71610-264; 53104-7555; 65015-619; 65757-726; 65841-122; 12496-0120; 42291-909; 43063-254; 43353-412; 43353-720; 43547-339; 49884-212; 50090-3340; 50458-309; 50458-350; 51759-740; 59746-020; 62135-929; 63304-949; 68382-156; 70518-1568; 70518-1763; 71335-0459; 71335-0740; 0615-8288; 72526-103; 52038-007; 65372-1105; 27241-002; 43547-340; 43547-341; 43547-342; 50090-3344; 50458-305; 50458-307; 50458-596; 63187-418; 65162-673; 65841-669; 69238-2110; 70518-2130; 70518-3104; 0904-6359; 0904-6362; 13668-036; 13668-038; 27241-001; 42291-910; 42291-912; 43353-432; 50090-3341; 50458-320; 50458-330; 63304-644; 65841-665; 68382-112; 68382-113; 68382-116; 68382-117; 69238-2109; 69238-2111; 69238-2112; 70518-0978; 72162-2037; 72526-101; 0904-6357; 40700-0031; 46602-0050; 65267-303; 71161-132; 13668-040
UNII L6UH7ZF8HC
Synonyms Risperidone | Risperdal Consta | Consta, Risperdal | Risperidal | R-64,766 | R 64,766 | R64,766 | R-64766 | R 64766 | R64766
Chemical Information
Molecular Formula C23H27FN4O2
CAS Registry Number 106266-06-2
SMILES CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sopor17.02.04.021; 19.02.04.0020.007819%-
Communication disorder19.19.01.0080.000182%-
Disturbance in social behaviour19.05.01.0180.000303%-
Cerebral cyst16.09.05.002; 17.18.05.0020.000182%-
Deformity08.01.03.022---
Cerebrovascular stenosis17.08.02.021; 24.04.06.0360.000242%-
Foaming at mouth07.05.05.019; 08.01.03.070; 17.02.05.0560.000121%-
Periodic limb movement disorder15.05.03.034; 17.15.04.006; 19.02.05.0090.000327%-
Faecal vomiting07.01.07.0130.000121%-
Portal venous gas07.01.06.0330.000121%-
Tachyphrenia17.03.03.007; 19.10.03.0100.000121%-
Excessive eye blinking06.05.01.004; 17.17.02.0100.000388%-
Sleep-related eating disorder14.03.01.012; 17.15.02.009; 19.02.03.0120.000327%-
Rabbit syndrome17.01.02.0250.000812%-
Frontotemporal dementia17.03.01.007; 19.20.02.0080.000303%-
Camptocormia15.03.05.004; 17.02.05.0530.000121%-
Herbal interaction08.06.03.0050.000182%-
Respiratory muscle weakness15.05.06.003; 17.05.03.017; 22.09.01.0040.000303%-
Systolic dysfunction02.04.02.0350.000121%-
Prerenal failure20.01.03.022; 24.06.02.0250.000485%-
Encephalitis autoimmune10.04.10.012; 16.32.01.006; 17.06.05.0020.000242%-
Hyponatraemic seizure14.05.04.008; 17.12.03.0250.000546%-
Palatal swelling07.05.04.0090.000303%-
Poor feeding infant14.03.02.022; 18.04.06.0060.000121%-
Disorganised speech17.02.08.017; 19.19.02.0050.000121%-
Unmasking of previously unidentified disease08.01.03.0800.000121%-
End stage renal disease20.01.03.0190.000364%-
Obsessive-compulsive symptom19.06.05.0100.000424%-
Selective eating disorder14.03.02.024; 19.09.01.0120.000242%-
Somatic symptom disorder of pregnancy18.02.02.025; 19.24.01.0080.000242%-
The 35th Page    First    Pre   35 36 37    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene